HTEC adds CRISPR, Insilico and Compass to index

On June 19 the Healthcare Technology and Innovation index (HTEC) added CRISPR Therapeutics, Insilico Medicine and Compass Pathways during its quarterly rebalance. The index cited developments in gene editing, artificial intelligence drug discovery and late-stage trials of a synthetic psilocybin therapy.

HTEC, launched in 2019 to give investors exposure to technology-driven healthcare, selects companies based on revenue concentration across nine strategic subsegments and research factors including technological and market leadership and ongoing R&D investment. The index is rebalanced quarterly to reflect scientific and commercial developments.

CRISPR Therapeutics joined the index as a gene-editing company. With Vertex, CRISPR co-developed CASGEVY, a gene-editing treatment for sickle cell disease and beta-thalassemia that edits a patient’s blood stem cells and returns them to the body. CASGEVY is in global rollout and CRISPR is pursuing pediatric approvals. The company’s pipeline also includes a small interfering RNA therapy intended to prevent blood clots, an allogeneic off-the-shelf CAR-T program targeting autoimmune conditions, and gene-editing candidates aimed at lowering triglycerides, LDL cholesterol and lipoprotein(a).

Insilico Medicine was added as the index’s first pure-play AI drug discovery company. The firm uses generative and predictive models to create preclinical drug candidates and partners with larger drugmakers for clinical development. Insilico was the first company to advance a drug candidate discovered entirely by generative AI into Phase II human trials. The company licenses its software to pharmaceutical partners and recently launched Science MMAI Gym, an infrastructure to train large language models for drug discovery tasks. Insilico produces about six to eight preclinical candidates a year and projects revenue growth from partnerships and new launches; FactSet estimates annual revenue rising to roughly $1.287 billion in fiscal 2026 from about $440 million in fiscal 2025, with projected margins above 80 percent.

Compass Pathways was added after completing final large-scale trials of COMP360, a proprietary synthetic psilocybin formulation for treatment-resistant depression. Trial results showed that one or two dosing sessions produced antidepressant effects lasting three to six months for some patients. In the United States an estimated three million people have treatment-resistant depression and fewer than 5 percent receive medications developed specifically for that condition. Compass plans to file a New Drug Application in the fourth quarter and referenced recent regulatory guidance, including a White House executive order directing the Drug Enforcement Administration to expedite consideration of rescheduling for psychedelic therapies that successfully complete Phase III trials. Compass has also reported early positive results for COMP360 in post-traumatic stress disorder studies.

HTEC is the underlying index for the Robo Global Healthcare Technology & Innovation ETF and the L&G Healthcare Technology & Innovation UCITS ETF (DOCT.LN). VettaFi provides the index methodology and receives a licensing fee; it is not the issuer, sponsor or seller of the ETFs and has no obligation or liability for ETF issuance, administration, marketing or trading.

The three additions were part of the quarterly rebalance intended to align the index with companies developing new treatment modalities across gene editing, artificial intelligence and psychedelic-assisted therapies.